Literature DB >> 7493678

Identification of latent myeloproliferative disease in patients with Budd-Chiari syndrome using X-chromosome inactivation patterns and in vitro erythroid colony formation.

J Acharya1, N B Westwood, B M Sawyer, M Messinezy, A K Burroughs, A B Mehta, T C Pearson.   

Abstract

Some patients with an early or latent myeloproliferative disorder (MPD) present with Budd-Chiari syndrome (BCS, hepatic vein thrombosis). Cell culture analysis of erythroid progenitors (BFU-E) can be used to discriminate primary from secondary MPD and examination of X-chromosome inactivation (in females) can be used to demonstrate clonality in neoplastic tissues. The present study used these techniques to examine whether a group of 7 female patients who presented with BCS had evidence to support a diagnosis of MPD. Unilateral X-inactivation and therefore clonality can be studied in females heterozygous for X-linked restriction fragment length polymorphisms (RFLP) by differences in methylation between active and inactive chromosomes. Probes for two polymorphic loci, phosphoglycerate kinase (PGK, at Xq13.3 [BstX1 RFLP]) and M27 beta (an anonymous locus DXS255 at Xp11.22 [Pst1 RFLP]) were used to study methylation patterns. All 7 patients were heterozygous using M27 beta and 2/7 were also heterozygous using the PGK probe. Polyclonal patterns of X-inactivation in granulocytes were demonstrated in 3/7, a skewed/monoclonal pattern in 1/7 and aberrant patterns in 3/7 using M27 beta. Two patients who had aberrant patterns of X inactivation with M27 beta demonstrated a skewed/monoclonal pattern with PGK. The results of BFU-E growth patterns and clonality were entirely concordant in 5/6 patients. Thus X-chromosome inactivation patterns, in conjunction with erythroid colony studies, can be used to assist in the diagnosis of an underlying MPD in BCS.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7493678     DOI: 10.1111/j.1600-0609.1995.tb00703.x

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   2.997


  3 in total

1.  Patients with polycythemia vera and essential thrombocythemia with prior malignancy do not have significantly worse outcome.

Authors:  Mohamad Cherry; Marylou Cardenas-Turanzas; Hannah Pham; Hagop Kantarjian; Jorge Cortes; Sherry Pierce; Lingsha Zhou; Srdan Verstovsek
Journal:  Leuk Res       Date:  2013-08-14       Impact factor: 3.156

Review 2.  Budd-Chiari syndrome: etiology, pathogenesis and diagnosis.

Authors:  Musa Aydinli; Yusuf Bayraktar
Journal:  World J Gastroenterol       Date:  2007-05-21       Impact factor: 5.742

3.  JAK2V617F positive polycythemia vera with paroxysmal nocturnal hemoglobinuria and visceral thromboses: a case report and review of the literature.

Authors:  Sevastianos Chatzidavid; Nefeli Giannakopoulou; Panagiotis Theodorou Diamantopoulos; Eleni Gavriilaki; Panagiota Katsiampoura; Eleftheria Lakiotaki; Stratigoula Sakellariou; Nora-Athina Viniou; Georgios Dryllis
Journal:  Thromb J       Date:  2021-03-10
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.